This study aims to understand how well liquid biopsies, a type of blood test, can predict if endometrial cancer will return. Researchers will collect blood and tissue samples from 1000 women with endometrial cancer to look for specific genetic changes, like in the TP53 gene. They will compare the results from these liquid biopsies to findings from tumor tissue to see if the blood tests can accurately detect cancer cells. This research could lead to a less invasive way to monitor endometrial cancer and help doctors understand how the cancer changes over time. You may be eligible if you are a woman aged 18 or older with endometrial cancer who is having or recently had surgery, and have not received prior treatment like chemotherapy or radiation.

Study design

This is an observational study involving 1000 women with endometrial cancer. It is not a treatment study, but rather looks at samples collected over time.

What's involved

You would provide blood samples at different times: before surgery, after surgery but before chemotherapy, and at the end of chemotherapy. Tissue samples would also be collected during your hysterectomy. You may also undergo a Pap smear.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, measuring circulating cell-free deoxyribonucleic acid (ccfDNA) mutations, will be assessed through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.